Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
Authors:
- Rachael V. McCalebRMRachael V. McCaleb
- Jill T. JohnsonJJJill T. Johnson
Open Access
- 1 January 2019
- journal article
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 5 (1) , e82-e85
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasisJournal of Oncology Pharmacy Practice, 2016
- Hypocalcaemia in patients with metastatic bone disease treated with denosumabEuropean Journal of Cancer, 2015
- Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating PhysiciansClinical Genitourinary Cancer, 2015
- A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairmentJournal of the Royal College of Physicians of Edinburgh, 2015
- Severe Hypocalcemia due to Denosumab in Metastatic Prostate CancerCase Reports in Nephrology, 2014
- Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studiesCurrent Medical Research and Opinion, 2013
- Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysisCancer Treatment Reviews, 2013
- Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?Expert Opinion on Biological Therapy, 2012
- Pharmacologic Prevention of Skeletal-Related Events in Cancer PatientsOrthopedics, 2010
- Pathogenesis of osteoblastic bone metastases from prostate cancerCancer, 2010